Literature DB >> 15793158

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Elizabeth D Hermsen1, Laurie B Hovde, George N Konstantinides, John C Rotschafer.   

Abstract

The purpose of this study was to compare the mutant prevention concentration (MPC) of ABT-492 to those of levofloxacin, moxifloxacin, and gatifloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The fluoroquinolones had comparable mutation selection windows, which is the ratio of MPC/MIC, for all isolates.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793158      PMCID： PMC1068586          DOI： 10.1128/AAC.49.4.1633-1635.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.

Authors:  Y Dong; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 3.  Antimicrobial resistance mechanisms: what's hot and what's not in respiratory pathogens.

Authors:  G S Tillotson; S J Watson
Journal:  Semin Respir Infect       Date:  2001-09

Review 4.  Stretching the mutant prevention concentration (MPC) beyond its limits.

Authors:  Heather J Smith; Kimberly A Nichol; Daryl J Hoban; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

5.  Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.

Authors:  Laurie B Hovde; Sarah E Rotschafer; Khalid H Ibrahim; Brent Gunderson; Elizabeth D Hermsen; John C Rotschafer
Journal:  Diagn Microbiol Infect Dis       Date:  2003-04       Impact factor: 2.803

6.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 7.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

8.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

9.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 10.  Emerging mechanisms of fluoroquinolone resistance.

Authors:  D C Hooper
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883
View more
  3 in total

1.  Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Pamela McGhee; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

2.  Mutant prevention concentrations of four carbapenems against gram-negative rods.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

3.  Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.

Authors:  Darlene Miller
Journal:  Clin Ophthalmol       Date:  2008-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.